Junshi & Mabwell Bioscience’s Junmaikang (biosimilar, adalimumab) Receive the NMPA’s Approval for the Treatment of RA & Two Other Indication
Shots:
- The NMPA has approved adalimumab biosimilar Junmaikang for the marketing authorization to treat RA, AS, Psoriasis. The therapy is being jointly developed by both companies
- Additionally, the therapy has received Major Scientific and Technological Support from the National 12th 5yr. plan for major new drug creation science and technology
- Adalimumab has sold under the brand name Humira & was used to treat RA, PsA, AS, CD, UC, Psoriasis, HS, uveitis & JIA
Ref: Big Molecule Watch | Image: Junshi
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
